Triple therapy in the treatment of patients with a combination of chronic obstructive pulmonary disease and bronchial asthma


Trushina E.Yu., Kostina E.M., Tipikin V.A., Orlova E.A.

Penza Institute for Advanced Medical Training – Campus Branch of the RMACPE, Penza, Russia
Patients with a combination of bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) are a special cohort that requires combination bronchodilator therapy in combination with glucocorticosteroid drugs. Patients with this pathology have difficulty achieving control of asthma and stabilization of COPD; they experience decreased lung function and frequent exacerbations requiring hospitalization, which leads to a decrease in quality of life. The possibilities for treating chronic obstructive diseases of the respiratory system have expanded significantly in recent years, primarily due to the emergence of new combination drugs. The International Guide for Global Initiative for Chronic Obstructive Lung Disease (2023) recommends starting treatment with triple inhalation therapy, including long-acting β2-agonists, long-acting anticholinergics, and inhaled glucocorticosteroids. This article presents data from studies of the clinical efficacy and safety of a fixed triple combination of beclomethasone dipropionate, glycopyrronium bromide and formoterol fumarate, available in the form of an extra-fine aerosol, which made it possible to optimize inhalation therapy in patients with a combination of BA and COPD.

About the Autors

Corresponding author: Elena Yu. Trushina, Cand. Sci. (Med.), Associate Professor at the Department of Pulmonology and Phthisiology, Penza Institute of Advanced Medical Training - Branch Campus of RMACPE, Penza, Russia;

Similar Articles

Бионика Медиа